In the study, patients taking the drug lived longer compared to those undergoing chemotherapy. "This study showed that they doubled that. They went from 6.5 to like 13 months on average," Dr. Zev ...

A new antibody‑drug conjugate nearly doubles survival and extends overall survival in advanced triple‑negative breast cancer, offering a more precise first‑line.

Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer ...

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

Therapeutic progress has accelerated, with multiple recent approvals improving outcomes across early-stage, muscle-invasive, and metastatic urothelial carcinoma. FGFR3 and HER2 protein expression by ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

The mRNA technology that helped end the COVID-19 pandemic may now hold the key to defeating cancer, and it exists because of President Trump’s Operation Warp Speed. Researchers at MD Anderson Cancer ...

Bridget Bradley had sat glued to her phone for three days when her doctor called with the verdict: Her cancer was finally ...